Virtual screening of quinoline derived library for SARS-COV-2 targeting viral entry and replication

Anju Anjua,b, Shubhra Chaturvedib, Vishakha Chaudharya,b, Pradeep Pantc, Firasat Hussaina and Anil Kumar Mishrab

aDepartment of Chemistry, University of Delhi, Delhi, India; bDivision of Cyclotron and Radiopharmaceutical Sciences, Institute of Nuclear Medicine and Allied Sciences, Defence Research and Development Organization Brig, Delhi, India; cDepartment of Chemistry, Indian Institute of Technology, New Delhi, India

Communicated by Ramaswamy H. Sarma

ABSTRACT
The COVID-19 pandemic infection has claimed many lives and added to the social, economic, and psychological distress. The contagious disease has quickly spread to almost 218 countries and territories following the regional outbreak in China. As the number of infected populations increases exponentially, there is a pressing demand for anti-COVID drugs and vaccines. Virtual screening provides possible leads while extensively cutting down the time and resources required for ab-initio drug design. We report structure-based virtual screening of a hundred plus library of quinoline drugs with established antiviral, antimalarial, antibiotic or kinase inhibitor activity. In this study, targets having a role in viral entry, viral assembly, and viral replication have been selected. The targets include: 1) RBD of receptor-binding domain spike protein S 2) Mpro Chymotrypsin main protease 3) Ppro Papain protease 4) RNA binding domain of Nucleocapsid Protein, and 5) RNA Dependent RNA polymerase from SARS-COV-2. An in-depth analysis of the interactions and G-score compared to the controls like hydroxyquinoline and remdesivir has been presented. The salient results are (1) higher scoring of antivirals as potential drugs (2) potential of afatinib by scoring as better inhibitor, and (3) biological explanation of the potency of afatinib. Further MD simulations and MM-PBSA calculations showed that afatinib works best to interfere with the the activity of RNA dependent RNA polymerase of SARS-COV-2, thereby inhibiting replication process of single stranded RNA virus.

Abbreviations: COVID-19: Corona Virus Disease-2019; SARS-COV-2: Severe Acute Respiratory Syndrome-2; FDA: Food and Drug Administration; PK: Pharmokinetic Properties; HCQ: Hydroxychloroquine; RdRp: RNA Dependent RNA Polymerase; BTK: Bruton Tyrosine Kinase; 2D: Two Dimensional

CONTACT Shubhra Chaturvedi shubhra@inmas.drdo.in; Anil Kumar Mishra akmishra@inmas.drdo.in

© 2021 Defence Research and Development Organization (DRDO) India

ARTICLE HISTORY
Received 14 September 2020
Accepted 31 March 2021

KEYWORDS
SARS-COV-2; RNA dependent RNA polymerase; Bruton Tyrosine kinase inhibitors; quinoline based FDA approved Drugs

Enrichment Screening Docking Studies Molecular Dynamics Simulations
1. Introduction

The pandemic outbreak of novel severe acute respiratory syndrome 2 or COVID-19 has claimed many lives and added to the social, economic, and psychological distress (Huang et al., 2020). Initially, the outbreak was local in Wuhan, China. With time the virus spread exponentially across borders through human contact. Considering the grave gravity, the World Health Organization (WHO) declared COVID-19 pandemic, a public health emergency of international concern (Law, 2020).

The continuously growing numbers of infections and mortality worldwide have called for a prompt therapeutic solution against COVID-19. Currently, no drugs or vaccines can specifically target the proteins in the corona virus to prevent diseases; hence the discovery of drugs or vaccines may be a milestone for all researchers. Based on clinical experiences while treating moderate to severe cases, three drugs-hydroxyquinoline, (Rothen & Bryarredy, 2020) remdesivir (Ko et al., 2020) and, lopinavir/ritonavir (Chu et al., 2004) have emerged with varied and contentious potential. Vaccine development is under progress. However, the chances of a breakthrough are bleak in the immediate future.

The pressing and expeditious demand for an effective therapeutic clubbed with limited biochemical knowledge, and complex-tedious-resource intensive drug designing have compelled researchers to switch to virtual screening for drug molecules. Drug repurposing through virtual screening is an innovative approach in the current time to quickly arrive at the promising scaffold (Kiplin Guy et al., 2020; Shah et al., 2020).

Taking leads from the limited and not-so successful clinical experiences, we hypothesize that virtual screening of drugs similar tohydroxyquinoline (HQ), remdesivir, and lopinavir/ritonavir might provide potential scaffolds. The three drugs target different pathways in effective scenarios: hydroxyquinoline acts as inhibitors during the entry of viral particles (Liu et al., 2020), remdesivir interfere with RNA replication (Yin et al., 2020), lopinavir/ritonavir (Cao et al., 2020) inhibits the activity of the virus by interfering with essential protein necessary for their life cycle. Among them, our interest focuses on hydroxyquinoline derived molecules because: (1) It is a proven antimalarial drug and antiviral, primarily acting as entry inhibitor and in some cases as endosomal pH modulator interfering with viral release, (2) It is an attractive pharmacophore for many protease inhibitors like the inhibitors for Fibroblast activated protein (FAP: Ramser et al., 2009), Bacillus thuringiensis serotype Kurstaki(BTK) proteases: (Barnard et al., 2014), Platelet-Derived Growth Factor (PDGFR), and as ALK5 inhibitors for TGF-β RI Kinase, and (3) It also acts as an immunomodulator. Thus, the heterocycle compound quinoline and it’s derivatives have found applications as an anticancer, anti(mycobacterial), antiviral, anticonvulsant, anti-inflammatory, and cardiovascular activity regulator (Marella et al., 2013).

A detailed insight into quinoline’s mechanism as an anti-COVID reflects three potential target classes: Class 1. As an inhibitor during viral entry, Class 2. As an inhibitor for transmembrane proteases, and Class 3. As a modulator of the immune response (Alexpandi et al., 2020). The first two target classes are primarily related to coronavirus, whereas the third class refers to the host.

The coronavirus entry into the host cell relies on the interaction of its spike glycoprotein with the Angiotensin receptor (ACE-2) of the host (human) (Shang et al., 2020). This entry mechanism is nearly universal for other members of the betacoronavirus of the coronaviridae family. The attachment to the host cells occurs through the S1 subunit of the betacoronavirus spike proteins, marking the viral fusion (H. Chakraborty et al., 2020). Quinoline derivatives have been reported to be an antagonist for ACE2 receptors. Figure 1 summarizes some potent antagonists for the ACE2 receptor.

The ACE2 receptor facilitates the entry of the viral particles through endocytosis and allows the transfer of a single stranded RNA strand into the host cell. Proteases also mediate the entire process at different steps. Main Protease is a cysteine protease that processes itself and then cleaves into several non-structural viral proteins having roles in viral replication. Thus, the protease has been suggested as one of the most facile and pragmatic target for drug repurposing owing to its role in the viral cycle and the ease of its biochemical assays (Dai et al., 2020).

Besides the above two targets that focus on viral particles, the host immune response can help prevent the replication and infection of the virus. However, an overactive immune system can cause a cytokine storm (C. Chakraborty & Bhattacharjya, 2020) leading to life-threatening conditions. An anti-COVID agent that can avoid the overactivation of human cells and modulates the immune response can be of therapeutic utility.

Hypothesizing that quinoline derivatives can emerge as a potent anti-COVID agent, targeting either of the above targets individually or in combination, we have screened an extensive library of hundred plus FDA approved quinoline based drugs using structure-based methods. Our focus has been to target the coronavirus, and hence the first two classes of targets have been considered. Among the class 1, we selected Receptor binding Domain of Spike protein of SARS-COV-2 (PDB ID 6M0J: Target 1), and among class 2 targets we have chosen: (a) Replicase polyprotein through Main Protease Mpro of SARS-COV-2 (PDB ID 5R80: Target 2) and Papain like protease (PDB ID 6W9C: Target 3) (b) Viral assembly through N-terminal RNA binding domain of Nucleocapsid protein of SARS-COV-2 (PDB ID 6M3M: Target 4), and (c) Viral RNA synthesis by targeting RNA Dependent RNA Polymerase (PDB ID 7BTF: Target 5)

2. Methods

2.1. Drugs Screened for analysing repurposing potential

One hundred thirty-one quinoline based different category of drugs that are FDA approved as antimalarial, antiviral, inhibitors of BTK and PDGFR, antibiotics and respiratory specific drugs were selected for structure-based screening. Appropriate controls viz., hydroxychloroquine and the non-quinoline drugs-remdesivir and galidesivir were chosen to compare the interactions. Molecular modelling Schrödinger
Software (v 2020) and Maestro 11.1 platform have been used for computational studies.

### 2.2. Targets selected to identify anti-COVID drug

Five targets were chosen for the study: (1) Receptor binding domain of SARS-COV-2 interacting with human ACE2 receptor (PDB ID: 6M0J) (2) chymotrypsin-like main protease of the virus MPro or 3CLPro, (PDB ID: 5R80) (3) Papain-like Protease from SARS-COV-2 (PDB ID: 6W9C), (4) N-terminal RNA binding domain of Nucleocapsid protein of SARS-COV-2 (PDB ID: 6M3M), and (5) RNA dependent RNA Polymerase from SARS-COV-2 (PDB ID: 7BTF). Also, two additional PDBs (6LU7, 6WTT) for the target Main Protease were chosen that are co-crystallized structures with different inhibitors. The coordinates and detailed sequence information was obtained from RCBS Protein Data Bank (www.rcsb.org).

The drugs were drawn using the Marwin Sketch tool as Mol2 format and imported in the software. After the ligand preparation using LigPrep v2.9 (OPLS3 force field, pH 7.0 ± 2.0) and protein preparation using Protein Preparation Wizard followed by binding site identification using SiteMap. The grid was generated with the box-dimensions (a) 120*120*120 for 6M0J against amino acids residue within the active site having Tyr495, Tyr505, Gly496, Asn487, and Gly502 (b) 80*80*80 for 6W9C within the active site having Asp103, Gly164, and Gly270, (c) 88*88*88 for 7BTF within the active site having Asp760 and Asp761, and (d) 112*112*112 for 6M3M including residues Ala51, Tyr112, and Tyr124. For the main of protease of SARS-COV-2, grid was generated against bound co-crystallized ligand N3 inhibitor with box dimension 72*72*72. After generation of grid docking of energy minimized ligands was performed using Extra Precision mode in Glide module.

For identification of possible receptor-ligand interaction analysis, more than five poses per ligand were selected, and docking parameters were computed using XP-visualizer. The drug interactions with the target, GScores, docking scores, and Glide EModel were thoroughly analysed to get the best interaction pose of ligand (drug) with the receptor. For all targets, appropriate controls were selected. Hydroxychloroquine serves as a control for Target S protein and MPro. Since galidesivir is screened as a potent drug for targeting RdRp polymerase, we used it as its control (Elfiky, 2020).

### 2.3. In silico ADME analysis

The pharmacokinetic (PK) properties of quinoline-based library viz., absorption, distribution, metabolism, excretion, and toxicity (ADMET) were calculated using the BioLuminate module of the Schrödinger Molecular Modelling Software (M/s Schrödinger, LLC, New York, NY, v. 2020).

### 2.4. Enrichment studies

Enrichment studies have been performed to assess the enrichment of active compounds in a screening process that
Table 1. GScore of top-ranking drugs for different category of targets 1) 6M0J 2)5R80 3) 6W9C 4) 6M3M 5) 7BTF.

| Target 1 6M0J | Target 2 5R80 | Target 3 6W9C | Target 4 6M3M | Target 5 7BTF |
|--------------|----------------|----------------|----------------|----------------|
| 10.8  | –9.04  | –8.57  | –8.51  | –8.97  |
| CP609754  | Afatinib  | Amodiaquine  | Primaquine  | EKB-569  |
| 9.72  | –8.77  | –8.53  | –8.50  | –7.81  |
| Afatinib  | Tezacaftor  | Afatinib  | Amodiaquine  | Camptothecin  |
| 9.6  | –8.48  | –8.4  | –7.61  | –7.53  |
| Saquinavir  | EKB-569  | Saquinavir  | Saquinavir  | Saquinavir  |
| 9.52  | –8.00  | –8.15  | –7.57  | –7.10  |
| Acalabrutinib  | Saquinavir  | SYL1655  | Elvitegravir  | Primaquine  |
| –9.41  | –7.75  | –8.09  | –7.29  | –7.04  |
| Rilapladib  | Batefenterol  | Batefenterol  | Imiquimod  | Dequalinium  |
| –9.02  | –7.48  | –7.57  | –7.26  | –7.04  |
| Plasmoquine  | Alatrofloxacin  | Quarfloxin  | Afatinib  | Elvitegravir  |
| –7.4  | –7.4  | –7.68  | –7.23  | –6.7  |
| Elvitegravir  | Elvitegravir  | Camptothecin  | Pamaqnine  | Imiquimod  |
| –6.91  | –6.3  | –6.67  | –5.15  | –6.4  |
| Amodiaquine  | Amodiaquine  | Elvitegravir  | Acalabrutinib  | Saquinavir  |
| –6.93  | –6.93  | –8.42  | –6.85  | –8.4  |
| SYL1683  | Remdesivir  | Remdesivir  | Remdesivir  | Remdesivir  |
| –6.75  | –8.02  | –8.42  | –6.85  | –8.4  |
| Remdesivir  | Remdesivir  | Remdesivir  | Remdesivir  | Remdesivir  |
| –6.05  | –5.3  | –5.11  | –4.99  | –5.37  |
| HQ  | HQ  | HQ  | HQ  | Galidesivir  |
| –4.9  | –4.32  | –5.77  | –3.58  | –6.1  |
| EKB-569  | Acalabrutinib  | Plasmoquine  | EKB-569  | Amodiaquine  |
| –4.01  | –4.84  | –2.63  | –5.4  | –5.4  |
| Plasmoquine  | Acalabrutinib  | Plasmoquine  | Acalabrutinib  | Acalabrutinib  |

includes a set of actives and a set of decoys (1000 decoys). The screening can be done with any program: Glide, Shape Screening, Phase. We used Glide program (docking tool) for the screening process. The active ligands input for the panel was taken from the output from the screening program having highest GScore with each therapeutic targets of SARS-COV-2 and, set of decoys were used from Schrodinger Maestro 11.0.

2.5. Molecular Dynamics simulation

Molecular dynamics simulations have been used extensively to explore the biological processes and ligand interactions in recent years (Dror et al., 2012; Duan et al., 2019; Hollingsworth & Dror, 2018; Santhanam et al., 2019). As through docking we have screened that afatinib is the best drug among all quinoline based drugs to target proteases of SARS-COV-2. Therefore, MD simulations have been performed with Afatinib drugs with all five therapeutics targets of SARS-COV-2. We performed all-atom explicit solvent MD simulations on the docked protein-afatinib (6MOJ-afatinib, 5R80-afatinib, 6W9C-afatinib, 7BTF-RdRp, 6M3M-Nprotein) complexes to evaluate the binding of the afatinib at the active site of the protein with respect to the simulations run length using AMBER software (Yang et al., 2016). The geometry of the ligands was optimized, and the bond, angle, dihedral, and partial charges [RESP] were generated using HF/6-31G* in Gaussian09 (Vanqulef et al., 2011) All the ligand parameters were saved in an AMBER compatible library file for each ligand considered for the study. All the complexes were immersed in a cubic water box (TIP3P water molecules) with counterions to ensure the overall electroneutrality of the systems. The protein counterparts were simulated with modified ff99SB force field (Maier et al., 2015), and the parameters for the counterions were taken from the literature (Joung & Cheatham, 2008).

We used Particle Mesh Ewald treatment (Cheatham et al., 1995) (for long-range electrostatics) with periodic boundary conditions for performing the simulations. All the systems underwent minimization to remove close contact in the systems, if any, followed by heating (50 ps, NVT) and equilibrating (5 ns). Finally, 100 ns long MD simulations were performed. For analysis, the Cpptraj code (Roe & Cheatham, 2013) was used for computing RMSD fluctuations, structure clustering, and the number of hydrogen bonds between ligand and protein molecules.

2.6. MM-PBSA calculation

LigPlot + software (Laskowski & Swindells, 2011) was used to sketch the interactions of the afatinib with protein. Molecular Mechanic/Poisson Boltzmann Surface Area (MM-PBSA) (Onufriev et al., 2000) calculations were performed to evaluate the binding proclivity of the ligand to the protein. The binding free energy gives information about different kind of interactions (potential energy and polar and non-polar solvation energy) and computed by using the following equation: (Bhardwaj et al., 2020)

$$
\Delta G_{\text{binding}} = G_{\text{complex}} - (G_{\text{receptor}} + G_{\text{ligand}})
$$

where $\Delta G_{\text{binding}}$ refers to change in energy after the formation of afatinib- ligand complex and $G_{\text{receptor}}$ is energy of free receptor without afatinib and $G_{\text{ligand}}$ is the energy of afatinib in unbound form.
3. Results and discussion
3.1. Docking and analysis

Quinoline pharmacophore is an important moiety according to the biological point of view. Its derivatives have been used in many fields for the progression of Alzheimer's diseases (Sureshkumar et al., 2020) as an antimalarial drug and target serine protease as an anticancer agent, and as an antimicrobial and antifungal agent (Marella et al., 2013; Desai et al., 2017). Hence in present work, we have reported in silico studies of quinoline-based, FDA-approved drugs for docking studies with crystal structures of SARS-COV-2.

Table 2. Illustrations of top-ranking antiviral, antimalarial and antibiotic, kinase inhibitor and anti-asthmatic Drugs.

| Drug  | Structure |
|-------|-----------|
| EKB-569 | ![Image](image1) |
| Hydroxychloroquine | ![Image](image2) |
| Amodiaquine | ![Image](image3) |
| Elvitegravir | ![Image](image4) |
| CP609754 | ![Image](image5) |
| Batefenterol | ![Image](image6) |
| Plasmoquine | ![Image](image7) |
| Rilapladib | ![Image](image8) |
| Acalabrutinib | ![Image](image9) |
| Afatinib | ![Image](image10) |
| Saquinavir | ![Image](image11) |
| Tezacaftor | ![Image](image12) |
| Quarfloxin | ![Image](image13) |
| Alatrofloxacin | ![Image](image14) |
| Pamaquine | ![Image](image15) |
| Imiquimod | ![Image](image16) |
| SYL1683 | ![Image](image17) |
| SYL1655 | ![Image](image18) |
| Dequalinium | ![Image](image19) |
Figure 2. 2D Ligand Interaction Diagram for Top scores drugs to target RBD of SARS-COV-2.

Figure 3. 2D Ligand Interaction Diagram for Top score drugs to target Main Protease of SARS-COV-2.
have screened a total of hundred plus FDA approved quinoline based drugs. They are categorised based on their approved clinical application. (their detailed properties and mode of action are displayed in supplementary).

Five targets are used for this study:

Class 1: Targeting viral entry

Target 1: RBD S protein that provides a viral surface for the attachment to host cell receptor ACE2.

Class 2: Targeting viral replication

Class 2a: Replicase polyprotein

Target 2: MPro and PLPro both are responsible for proteolysis of viral polyprotein into functional unit.

Target 3: Papain-like proteases

Class 2b: Viral assembly

Target 4: Nucleocapsid proteins

Class 2c: Viral RNA synthesis by targeting RNA Dependent RNA Polymerase

Target 5: RdRp is responsible for replicating viral genome

*Tables 1 and 2 summarize the top-ranking compounds with their respective targets and their 2D Ligand Interaction Diagram (LID) are displayed in Figures 2–6.*

### 3.1.1. Docking results for class 1, target 1: viral entry

The antivirals were the top scorers when averaged over the docking scores and energy (Figure 7(a)). Even though kinase inhibitors average values were lower, the top rankers included inhibitors with better potential like Afatinib, Acalabrutinib and Rilapladib.

RBD S protein is responsible for the entry of SARS-COV-2 into a host cell, which simultaneously binds with ACE2 and TMPRSS into the host cell. Therefore, targeting RBD Spike protein of SARS-COV-2 is the most prior step (Lan et al., 2020). Among all the screened drugs CP-609754 had the highest G-Score of $-10.8 \text{kcal/mol}$. The binding was approximately 78.51% higher than hydroxyquinoline (having a G-score of $-6.05 \text{kcal/mol}$). An insight into its binding highlight the additional hydrophobic energy due to the terminal propargyl group. However, not all the amino acids lining the binding pocket adds to the interaction, and the significant contributors are given in Table 3. A good ligand should have a combination of best fit and docking parameters. The next ranking molecules were Saquinavir and Afatinib, showing a G-score of $-9.6 \text{kcal/mol}$ and $-9.72 \text{kcal/mol}$, respectively. Docking pose reveals a higher contribution from polar forces like the H bonding. Saquinavir and Afatinib have the best combination of both G-score and amino acid participation.
Figure 5. 2D Ligand Interaction Diagram for Top score drugs to target Nucleocapsid Protein of SARS-COV-2.

Figure 6. 2D Ligand Interaction Diagram for Top score drugs to target RNA dependent RNA polymerase of SARS-COV-2.
resulting in a better fit. Saquinavir has more fitting in the active site of binding pocket as there are five hydrogen bonds between heteroatoms of saquinavir and within the active site of RBD. Three oxygen forms hydrogen bonds with Gln96, Arg403, Gln406, Gln409 and Lys417. Also, the amine group of the alkyl chain forms a hydrogen bond with Glu406. Aromatic ring in saquinavir forms π-π stacking with Arg403. The residue in the active site with which saquinavir binds are Arg408, Lys417, Tyr505, Gly416, Ile418, which are crucial for binding with RBD of SARS-COV-2 (Sachdeva et al., 2020).

Acalabrutinib exhibited the G-score of −9.52 kcal/mol with key interactions between oxygen atoms and Arg403 and Gly505 as H-bonding and π-π stacking of aromatic ring with Tyr505. The protonated nitrogen forms a salt bridge with Asp405.

Next in series were rilapladib and plasmoquine with G-score −9.41 kcal/mol and −9.02 kcal/mol (Docking Parameters Table 4). Rest of drugs details have provided in Table S7.

The screened drugs having a G-Score greater than 8.00 kcal/mol showed in general, the binding interactions with the following residues: H-bonding with Gln496, Lys417, and Arg408, π-π stacking with Tyr505, Tyr453, Tyr449, Glu37, Asp38, Lys68 are considered as potent drugs for blocking the Spike-ACE2 interactions.
Table 3. Interacting amino acids for Drugs with RBD of SARS-COV-2 (6M0J) with G-Score above Hydroxyquinoline and active side residue are marked bold.

| Compound (6M0J)                  | Mode of Action               | Hydrophobic          | Polar             | Hydrogen bonding                  | Charged          | n-π stacking |
|----------------------------------|------------------------------|----------------------|-------------------|-----------------------------------|------------------|--------------|
| Farnesyl transferase inhibitor   |                              | Val93, Ala387, Ala386, Ala387, Phe390 | Asn33, Gln96, Thr92, Gln388 | Thr92                             | Lys26, Asp30, Glu37, Arg393 |              |
| CP609754                         | Anti-HIV Protease inhibitor  | Chain A: Phe390, Ala387, Ala386, Val93, Leu29, Chain E: Tyr505, Ile418, Gly416 | Gln388, Asn33, Gln96, Thr92, Glu409, Gln406, Arg403 | Chain E Arg403, Chain A: Glu37, Arg393, Asp30, Lys26, Chain E: Glu406, Asp405, Arg403, Arg408, Lys417 |              |
| Saquinavir                        | Tyrosine Kinase inhibitor; Epidermal Growth Factor Receptor (EGFR) inhibitor | Chain A: Ala387, Ala386, Val93, Pro389, Chain E: Tyr453, Ile418, Gly416 | His33, Gln388, Gln96, Thr92, Gln409 | Chain E: Tyr453, Arg403, Chain A: Glu37, Asp38, Asp30, Lys353, Lys26, Arg393, Chain E: Arg403, |
| Afatinib                          | Bruton Tyrosine Kinase Inhibitor | Chain A: Pro398, Ala387, Ala386, Leu29, Met383, Phe356, Chain E: Tyr505, Gln404, Val503, Gly502 | Gln388, Asn33, Thr324, Chain A: Arg403, Asp405 | Chain E: Asp405, Arg408, Chain A: Glu37, Arg393, Asp405 | |
| Acalabrutinib                    | Lipoprotein associated phospholipase (A) Lp-plA2 Inhibitor | Chain A: Pro398, Ala387, Ala386, Phe390, Ala386, Val93, Chain E: Tyr505, Leu455, Gly504 | Asn33, Gln388, Thr92, Gln96 | Chain A: Asp30, Chain E: Arg403 | Chain A: Asp30, Lys26, Arg393, Chain E: Lys417, Arg408, Arg403 |
| Rilapladib                       | Synthetic Antimalarial Drug | Chain A: Pro389, Ala387, Ala386, Val93, Leu29, Chain E: Tyr505 | Asn33, Gln388, Thr92, Gln96 | Chain A: Asn33, Asn33, Gln96, Arg393, Glu37, Chain E: Tyr505, Arg403 | Chain A: Lys26, Asp30, Glu37, Arg393, Chain E: Arg403, Asp405 |
| Plasmoquine                      |                              |                      |                   |                                   |                  |              |

(continued)
3.1.2. Docking results for targets of Class 2: Replication

Target 1: Interaction analysis within active site of SARS-COV-2 main protease M\textsuperscript{Pro} (three PDB IDs: 5R80-complexed with Z18197050, 6WTT-complexed with inhibitor GC376, 6LU7-with inhibitor N3)

When the quinoline library was docked on M\textsuperscript{Pro} PDB (5R80), and the average docking scores and binding energies compared, respiratory specific and antivirals emerged as most promising (Figure 7(b)).

M\textsuperscript{Pro} or the chymotrypsin like protease (3CLpro)/C30 Endopeptidase produces non-structural proteins that later play a role in mediating the replication of the virus (Elzupir, 2020). Therefore, inhibiting the activity of this enzyme can block viral replication. Once inside the host cell, the proteases of the virus cleave the mRNA into structural and non-structural proteins. The protease belongs to cysteine protease family with cysteine-histidine catalytic dyad. 3CLpro monomer has three domains, domain I (residues 8-101),

### Table 3. Continued.

| Compound (6M0J) | Mode of Action | Hydrophobic | Polar | Hydrogen bonding | \(\pi-\pi\) stacking | Charged |
|-----------------|----------------|-------------|-------|------------------|----------------------|---------|
| **Amodiaquine** | Anti-malarial Drug | Chain E: Tyr\textsuperscript{453}, Tyr\textsuperscript{495}, Gln\textsuperscript{496}, Phe\textsuperscript{497}, Tyr\textsuperscript{505} | Chain A: Phe\textsuperscript{390}, Pro\textsuperscript{389}, Ala\textsuperscript{387}, Ala\textsuperscript{386} |
| **Hydroxyquinoline** | Antimalarial Drug | Chain A: Leu\textsuperscript{29}, Val\textsuperscript{93}, Phe\textsuperscript{390}, Pro\textsuperscript{389}, Ala\textsuperscript{387}, Ala\textsuperscript{386}, Chain E: Gly\textsuperscript{504}, Tyr\textsuperscript{505} |
| **SYL1683** | Anti-HIV Inhibitor | Chain A: Pro\textsuperscript{389}, Ala\textsuperscript{387}, Ala\textsuperscript{386}, Met\textsuperscript{383}, Phe\textsuperscript{356}, Gly\textsuperscript{354} |
| **EKB-569** | Anti-HIV Inhibitor | Chain A: Leu\textsuperscript{29}, Val\textsuperscript{93}, Phe\textsuperscript{390}, Pro\textsuperscript{389}, Ala\textsuperscript{387}, Ala\textsuperscript{386}, Chain E: Tyr\textsuperscript{505}, Tyr\textsuperscript{495}, Gly\textsuperscript{496}, Tyr\textsuperscript{453} |
| **Elvitegravir** | Antiviral Drug | Chain A: Pro\textsuperscript{389}, Phe\textsuperscript{390}, Chain E: Tyr\textsuperscript{505}, Tyr\textsuperscript{495}, Gly\textsuperscript{496}, Tyr\textsuperscript{453}, Ile\textsuperscript{418}, Gly\textsuperscript{416} |
| **Remdesivir** | | | | | | |

8474 A. ANJU ET AL.
domain II (residues 102-184) and domain III (residues 201-303), and a long loop (residues 185-200) connects domains II and III. The active site of 3CLpro is located in the gap between domains I and II, and has a Cys-His catalytic dyad (Cys145 and His41 (Vatansever et al., 2020). Recently, aminoquinolines have been reported as inhibitors of certain cysteine proteases (Braga et al., 2017). However, a greater number of antivirals and inhibitors scored above hydroxyquinoline. Only tezacaftor, that is a cystic fibrosis transmembrane conductance regulator (CFTR) was able to score a higher G-Score.

Molecules with docking scores more than that of hydroxyquinoline (G-score \(-9.04\)) are summarised in Table 1. Ligand Interaction Diagram for top scorers with 5R80 are shown in Figure 3 and their interaction information are provided in (Table 5). Afatinib has the best G-score of \(-9.04\) kcal/mol, followed by tezacaftor G-score of \(-8.77\) kcal/mol (Docking Parameters) (Table 6). Table G-score of rest of drugs have represented in Table S8SI.

Among all the drugs, afatinib with GScore \(-9.04\) was well fitted into the binding pocket of MPro and the binding was 67.4% higher than that of HCQ. A similar trend was observed when the molecules were docked on other PDBs of MPro (6WTT, 6LU7). Afatinib was the top scorer with GScore of \(-9.3\) kcal/mol with 6WTT and \(-9.943\) kcal/mol with 6LU7 and also showed binding with catalytic dyad forming \(\pi-\pi\) stacking with His41 and interaction with Cys145. The binding pocket is primarily
Table 5. Ligand Interaction information for top scoring drugs to inhibit the activity of main protease of SARS-COV-2 (SR80).

| Compound | Mode of Action | Hydrophobic | Polar | II-III stacking | H-Bond | Charged |
|----------|----------------|-------------|-------|-----------------|--------|---------|
| Afatinib | Tyrosine Kinase inhibitor; Epidermal Growth Factor Receptor (EGFR) inhibitor | Phe140, Leu141, Gly143, Cys145, Leu27, Cys44, Tyr54, Pro52, Met49, Met165, Leu167, Pro168 | Asn142, Ser144, Thr26, Thr25, His163, His164, Gln189, Gln192 | | Glu166 | Hip41 |
|         | Cystic Fibrosis Transmembrane Conductance regulator | Leu141, Gly143, Cys145, Met49, Met165, Cys44, Met49, Pro52, Tyr54 | Gln189, His164, His163, Gln189, Gln192, His164, His163, Ser46 | | | |
| Tezacactor | An irreversible Epidermal Receptor Growth receptor Tyrosine kinase | Phe140, Leu141, Gly143, Cys145, Met165, Cys44, Met49, Pro52, Tyr54 | Asn142, Thr190, Thr14, Ser46, Thr25, His164, His163 | | Glu166, Gln189, Thr25 | Hip41, Hip41, Arg188, Glu166 |
| EKB-569 | Anti-HIV Protease inhibitor | Tyr54, Cys44, Met49, Phe140, Leu141, Cys145, Met165, Leu167, Pro168 | Thr190, Ser46, Asn142, Thr190, Thr25, His163, His164 | | Glu166, Hip41 | Hip41, Hip41, Arg188, Glu166 |
| Saquinavir | \(\beta_2\) adrenoceptors agonist, muscarinic receptor antagonist | Leu167, Met165, Pro168, Phe140, Leu141, Met49, Gly170, Gly138, Val171 | Gln189, His164, Thr190, His163, Gln192, Thr169, His172, Ser139, Asn142 | | Gly138, Glu166, Thr169 | Hip41, Hip41, Arg188, Asp187, Glu166 |
| Batfentol | Antibacterial Antineoplastic DNA topoisomerase inhibitor | Phe140, Leu141, Cys145, Gly143, Met49, Tyr54 | Gln189, Thr190, His164, His164, Asn142, Hip41 | | Glu166, Asn142, Phe140, Glu166, Hip41 | Hip41, Hip41, Arg188, Asp187, Glu166 |
| Alatrofloxacain | | | | | | |

(continued)
| Compound               | Mode of Action                                                                 | Hydrophobic          | Polar                        | H-bond             | Charged       |
|------------------------|-------------------------------------------------------------------------------|----------------------|------------------------------|--------------------|---------------|
| Co-crystallized Ligand-| Z1819750                                                                      |                      |                              |                    |               |
|                        |                                                                               | Pro168, Leu167,      | Gln189, Thr190, Gln192       | Hip41, Arg188,     |               |
|                        |                                                                               | Met165, Met49,       |                              | Asp187, Glu166     |               |
|                        |                                                                               | Cys44, Tyr54         |                              |                    |               |
| Hydroxychloroquine     | Anti-HIV Inhibitor                                                            |                      |                              |                    |               |
|                        |                                                                               | Pro168, Leu167,      | Gln189, Thr190, Gln192       | Hip41, Arg188,     |               |
|                        |                                                                               | Met165, Val186,      |                              | Asp187, Glu166     |               |
|                        |                                                                               | Tyr54, Pro52, Met49, |                              |                    |               |
|                        |                                                                               | Cys44, Cys145        |                              |                    |               |
| Elvitegravir            | Antimalarial Drug                                                             |                      |                              |                    |               |
|                        |                                                                               | Met49, Leu27,        | Gln189, Thr190, Gln192       | Hip41, Arg188,     |               |
|                        |                                                                               | Pro168, Leu167,      |                              | Asp187, Glu166     |               |
|                        |                                                                               | Met165, Gly170,      |                              |                    |               |
|                        |                                                                               | Leu141, Gly143       |                              |                    |               |
| Amodiaquine             | Tyrosine Kinase inhibitor; Epidermal Growth Factor Receptor (EGFR) inhibitor  |                      |                              |                    |               |
|                        |                                                                               | Leu167, Met165,      | Gln192, Gln189, Thr190, Hie164, Ser146, Thr45, Thr25 |
|                        |                                                                               | Pro168, Met49,       |                              |                    |               |
|                        |                                                                               | Tyr54, Cys44, Gly143 |                              |                    |               |
| Acalabrutinib           | Antimalarial Drug                                                             |                      |                              |                    |               |
|                        |                                                                               | Met165, Pro168,      | Gln189, Thr190, Hie164, His163, Asn144, Hie172 |
|                        |                                                                               | Met49, Phe140, Leu141, Gly143, Cys145 |
| Plasmoquine             | Antiviral Drug                                                                 |                      |                              |                    |               |
|                        |                                                                               | Ala191, Pro168, Phe140, Leu141, Met165, Gly143 |
| Remdesivir              |                                                                                |                      |                              |                    |               |
marked by the catalytic dyad of amino acids Cys145 and His41 (Khan et al., 2020). All reported residues in the active site of binding pocket of Mpro and as evident in the co-crystallized PDB bind to afatinib. The quinoline ring in afatinib showed π-π stacking with Hip41 along with the H-bond between protonated nitrogen with Glu166 and covalent interaction of chlorine atom with Asn142 and Gly143. Also, afatinib bind with 12 Hydrophobic residues and with ten polar residues. Therefore, afatinib can be considered the potent drug for targeting main protease of SARS-COV-2.

3.1.3. Target 3: Interaction characterization of quinoline based drugs with SARS-COV-2 papain like protease

When the quinoline library was docked on PLPro PDB (6W9C), averaged G-scores, docking scores and binding energies were compared, respiratory specific are served as most promising (Figure 7(c)). PLPro is responsible for the cleavages of N-terminus of the replicate poly-protein to release non-structured proteins (Nsp1-3), essential for correcting virus replication. PLPro was also confirmed to be significant in antagonizing the innate immunity of the host. As an indispensable enzyme in the process of coronavirus replication and infection of the host, PLPro has been a popular target for coronavirus inhibitors. It is very valuable for targeting PLPro to treat coronavirus infections, but no inhibitor has been approved by the FDA for marketing. All quinoline based drugs were docked with crystal structure of PLpro (PDB ID 6W9C). Docking Parameters for high scoring drugs are displayed in Table 7. Remdesivir was considered as control with GScore of $-8.4$ kcal/mol. Among all screened drugs again, amodiaquine, afatinib and saquinavir having G-scores $-8.57$, $-8.53$ and $-8.4$ respectively scored above remdesivir. The binding pocket is primarily marked by the amino acids Gly270, Asp103, Gly164 and their interaction information are provided in Table 8. Heteroatoms

| Table 6. Docking Parameters for top scoring drugs with main protease of SARS-COV-2 (PDB ID 5R80). |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Drugs           | GScore          | DScore          | Lipophilic     | Hbond           | EModel         |
| Afatinib        | $-9.04$         | $-7.86$         | $-5.44$        | $-2.03$         | $-82.179$      |
| Tezacaftor      | $-8.77$         | $-8.77$         | $-3.44$        | $-3.75$         | $-73.611$      |
| EKB-569         | $-8.48$         | $-7.29$         | $-4.91$        | $-0.6$          | $-80.502$      |
| Saquinavir      | $-8.0$          | $-8.32$         | $-4.46$        | $-1.96$         | $-113.245$     |
| Batefenterol    | $-7.75$         | $-6.95$         | $-3.46$        | $-0.56$         | $-77.398$      |
| Alatrofloxacin  | $-7.48$         | $-6.23$         | $-3.73$        | $2.9$           | $-80.502$      |
| Elvitegravir    | $-7.4$          | $-7.2$          | $-5.23$        | $1.3$           | $-83.219$      |
| Amodiaquine     | $-6.3$          | $-6.3$          | $-4.52$        | $1.57$          | $-63.984$      |
| Remdesivir      | $-8.02$         | $-8.018$        | $-5.22$        | $2.73$          | $-82.640$      |
| HQ              | $-5.3$          | $-5.2$          | $-1.2$         | $0.6$           | $-82.284$      |
| Acalabrutinib   | $-4.32$         | $-4.31$         | $-3.85$        | $0.82$          | $-72.269$      |
| Plasmoquine     | $-4.01$         | $-3.78$         | $-3.85$        | $0.5$           | $-40.857$      |

Figure 9. Receiver Operator Characteristics Curve for all active drugs with therapeutics targets of SARS-COV-2.
of amodiaquine viz., protonated nitrogen and nitrogen atom of quinoline ring form H-bond with Asn109, Asp108, Val159 and Glu161. Other residues in the binding pocket of PVD^{6M3M} with Amodiaquine forms covalent interaction are Cys270, Leu162, Trp106, Val159, Gly160.

Ligand Interaction Diagram for top scorers with 6W9C are displayed in Figure 4. Docking parameters for rest of drugs with 6W9C are provided in Table 9^{aSI}.

### 3.1.4. Target 4: Interaction characterization of quinoline based drugs with RNA binding domain of nucleocapsid protein of SARS-COV-2

When the quinoline library was docked on PDB (6M3M), average GScores and the average docking scores and binding energies compared, respiratory specific drugs emerged as most promising (Figure 7(d)).

The SARS-COV-2 nucleocapsid RNA binding protein plays a vital role in viral RNA transcription and replication. As the name is suggestive of its function, the primary function of the N-protein is binding to the viral RNA genome and packing into a long helical nucleocapsid structure or ribonucleoprotein (RNP) complex (Dutta et al., 2020). Experimental studies revealed that N-protein maintains highly ordered RNA conformation suitable for replicating and transcribing the viral genome. The protein is speculated to regulate host-pathogen interactions, such as actin reorganization, host cell cycle progression, and apoptosis. The N protein itself is highly immunogenic and abundantly expressed protein during infection, capable of inducing protective immune responses against SARS-COV-2 (Kang et al., 2020).

The docking Parameters and Ligand Interaction amino acids are provided in Tables 9 and 8 respectively. The drugs that have GScore greater than or equal to −7 are considered best candidates and bind with residues Ala51, Tyr112, Tyr124 within the active site are considered potent drugs for targeting N protein. Docking with Nucleocapsid proteins of SARS-COV-2 suggest that primaquine and amodiaquine antimalarial drugs serve as the best inhibitor with G-score −8.5, followed by saquinavir with GScore −7.61 kcal/mol and and elvitegravir with −7.57 kcal/mol respectively (Table 1). Key interactions are H-bond between protonated nitrogen atom in primaquine and Trp133, π-π stacking with Tyr110 and Lys66, and covalent interactions with Ala51, Thr50, Asn49, Ty124 and Tyr110, which are crucial for binding with RNA binding domain of N Protein, and makes it the best drug to target Nucleocapsid protein of SARS-COV-2. The GScore of primaquine is 70.2% higher than HCQ. Ligand Interaction Diagram for top scorers are displayed in Figure 5 with 6M3M. Docking parameters for rest of drugs with 6M3M are provided in Table S10^{aSI}.

#### 3.1.5. Target 5: Interaction characterization of quinoline based drugs with SARS-COV-2 RNA dependent RNA polymerase (PDB ID 7BTF)

The quinoline library was docked on PDB (7BTF), and the average docking scores and binding energies compared kinase inhibitors emerged as most promising (Figure 7(e)).

RdRP is a vital enzyme for the life cycle of the single-stranded RNA coronavirus (Elfiky, 2020). The function of RdRp is to convert a single-stranded RNA virus into many single-stranded RNA viruses. RdRp active site is conserved among different organisms, while two successive, surface-exposed aspartate residues are protruding from a beta-turn motif (Yin et al., 2020).

Ligand Interaction Diagram for top scorers with 7BTF are displayed in Figure 6. The binding pocket is primarily marked by the amino acids Asp760 and Asp761. As galidesivir is considered as the best ligand for RdRp, it was used as a control with a GScore of −5.375 kcal/mol. Docking with RdRp suggests that EKB-569 has the highest binding with GScore value −8.97 kcal/mol followed by campothecin with GScore −7.81 kcal/mol. The docking parameters and interaction amino acids informations are provided in Tables 11 and 12 respectively. The binding of EKB-569 with RdRp was approximately 66.8% higher than that of galidesivir. The protonated nitrogen and oxygen atoms of EKB-569 form hydrogen bonding with Asp760 and Asp761, which is crucial for binding within the active site of RNA dependent RNA polymerase from SARS-COV-2. The interactions also include π-π stacking between the aromatic and quinoline rings with Lys621, Arg553, and a hydrogen bond with Arg553.

The drugs having GScore greater than or equal to −7.00 kcal/mol and bind with active site residue Asp760 and Asp761 within the active site are considered as potent drugs to target RdRp from SARS-COV-2.

Ligand Interaction Diagram for top scorers with 7BTF are displayed in Figure 6. Docking parameters rest of drugs with 7BTF are provided in Table S11^{aSI}.

A preliminary analysis based on higher score than the control hydroxyquinoline (Table 1) reflects the following. Overall, among all the drugs amodiaquine serves as best for all the targets. Afinatinib and saquinavir were above the HQ in four of the targets. This analysis brings out the contenders that may target multiple targets. Elvitegravir and EKB-569 reserved their roles as inhibitors of proteases and RdRp polymerase. Rilaplabid emerged as a potential candidate for inhibition of viral entry with binding potential with ACE2 (Tables 11 and 12).

### 3.3. In silico ADME properties

The compilation of bioactivity parameters is presented in Table S6^{aSI}. Results of in silico ADME analysis indicate the following results: (Figure 8)
Table 8. Interacting amino acids for Drugs having G-Score above Hydroxyquinoline for Papain Protease of SARS-COV-2 (PDB ID: 6W9C).

| Compound                  | Mode of Action                           | Hydrophobic          | Polar       | π-π Stacking          | H-Bond             | Charged               |
|---------------------------|------------------------------------------|----------------------|-------------|-----------------------|---------------------|-----------------------|
| Amodiaquine               | Antimalarial, Anti-inflammatory           | Chain A: Gly160, Leu162 | Chain A: Asn109, Gln269  | Chain A: Glu161     | Chain A: Asp108, Chain B: Glu161, Chain C: Asp108 |
|                           |                                           | Chain B: Val159, Leu162, Val159, Cys270, Gly160 | Chain B: Asn109, Gln269, Thr158, Gln269 | Chain B: Asn109, Thr158, Gln269 | Chain B: Glu161, Chain C: Asp108, Asp108 |
| Afatinib                  | Antimyalarial, Anti-inflammatory          | Chain A: Gly160, Leu162 | Chain A: Asn109, Gln269  | Chain A: Glu161     | Chain A: Asp108, Chain B: Glu161, Chain C: Glu161 |
|                           |                                           | Chain B: Val159, Leu162, Val159, Cys270, Gly160 | Chain B: Asn109, Gln269, Thr158, Gln269 | Chain B: Asn109, Thr158, Gln269 | Chain B: Glu161, Chain C: Asp108, Asp108 |
| Saquinavir                | Anti-HIV                                  | Chain A: Leu162, Val159, Gly160  | Chain A: Thr158, Asn109, Gln269  | Chain B: Leu162, Gly160 | Chain B: Glu161, Chain C: Glu161, Asp108 |
|                           | Protease inhibitor                        | Chain B: Val159, Leu162, Val159, Cys270, Gly160 | Chain B: Thr158, Asn109, Gln269, Thr158, Gln269 | Chain B: Thr158, Asn109, Gln269 | Chain B: Glu161, Chain C: Asp108, Asp108 |
|                           |                                           | Chain C: Val159, Leu162, Val159, Cys270, Gly160 | Chain C: Thr158, Asn109, Gln269, Thr158, Gln269 | Chain C: Thr158, Asn109, Gln269 | Chain C: Glu161, Chain C: Glu161, Asp108 |
| SYL1655                   | Anti-HIV                                  | Chain A: Val159, Gly160, Leu162  | Chain A: Thr58, Ser85, His89 | Chain A: Glu161      | Chain A: Asp108, Glu161, Chain C: Glu161, Arg82, Lys157 |
|                           | Protease inhibitor                        | Chain B: Val159, Leu162, Cys270, Gly160 | Chain B: Asn156, His89 | Chain B: Glu161     | Chain B: Glu161, Chain C: Glu161 |
|                           |                                           | Chain C: Cys270, Leu162, Val159 | Chain C: Thr58, Ser85, His89 | Chain C: Asp108, Chain B: Glu161, Chain C: Lys92, Asp108 |
Table 8. Continued.

| Compound          | Mode of Action          | Hydrophobic          | Polar                | H-Bond                | Charged     |
|-------------------|-------------------------|----------------------|----------------------|-----------------------|-------------|
|                   |                         | Chain A: Val159, Leu162, Ala86, Gly160 | Chain A: Thr158, Ser85, His89, Gln269 | Chain A: Val159 | Chain A: Arg82, Glu161 |
| Quarfloxin        |                         | Chain B: Val159, Cys270, Chain C: Leu162, Cys270, Gly160 | Chain B: Gln269, His89, Asn109, Chain C: Asn109, Gln269 | Chain B: Asp108     | Chain C: Glu161 |
|                   |                         |                       | Chain B: Val159      |                       | Chain B: Gln161 |
| Hydroxychloroquine|                         | Chain A: Leu162, Gly160 | Chain A: Thr158, Gln269, Chain A: Val159, Thr158, Chain A: Gln160 | Chain A: Gln160 | Chain A: Glu161 |
|                   |                         | Chain B: Leu162, Val159, Cys270, Gly160 | Chain B: Thr158, Gln269, Asn109, Chain B: Thr158, Gln269 | Chain B: Val159, Thr158, Gln269 | Chain B: Gln161, Asp108     |
|                   |                         |                       | Chain B: Thr158, Gln269, Chain A: Thr158, Gln269, Asn109 | Chain B: Gln160, Thr158, Gln269 | Chain A: Asp108     |
|                   |                         |                       | Chain C: Asn109, Gln269 | Chain C: Asn109, Gln269 | Chain B: Glu161, Asp108 |
| Topoisomerase Inhibitor  |                         | Chain A: Leu162, Val159 | Chain A: Thr158, Gln269, Chain A: Thr158, Gln269 | Chain A: Thr158, Gln269 | Chain C: Glu161, Asp108 |
|                   |                         | Chain B: Val159, Gly160, Leu162, Cys270, Gly160 | Chain B: Asp108, Chain B: Gln160 | Chain A: Asp108, Glu161 | Chain A: Asp108     |
|                   |                         |                       | Chain B: Thr158, Gln269, Chain C: Thr158, Gln269 | Chain C: Asn109, Gln269 | Chain C: Glu161, Asp108 |
| Campothecin       |                         | Chain A: Thr158, Asn109, Gln269 | Chain A: Thr158, Asn109, Gln269 | Chain A: Thr158, Asn109, Gln269 | Chain A: Glu161 |
|                   |                         | Chain A: Leu162, Gly160, Cys270, Val159 | Chain A: Thr158, Asn109, Gln269 | Chain A: Leu162, Val159 | Chain A: Glu161 |
|                   |                         | Chain C: Leu162, Gly160, Val159 | Chain B: Thr158, Gln269, Asn109, Chain C: Asn109, Gln269 | Chain B: Thr158, Gln269, Asn109 | Chain A: Cys108 |

(continued)
| Compound | Mode of Action | Hydrophobic | Polar | π-π Stacking | H-Bond | Charged |
|----------|---------------|-------------|-------|--------------|--------|---------|
| **Antimalarial Drug** | Chain A: Leu162, Gly160 | Chain B: Leu162, Gly160, Cys270, Val159 | Chain A: Thr158, Gln269, Asn109, His89 | Chain B: Asn109 | Chain A: Glu161 |
| **Tyrosine Kinase inhibitor; Epidermal Growth Factor Receptor (EGFR) inhibitor** | Chain A: Leu162, Gly160, Val159 | Chain B: Leu162, Gly160, Cys270, Chain C: Leu162, Gly160, Ala86, Val159, Cys270 | Chain A: Asn109, Gln269, His89, Thr158, Ser85 | Chain B: Asn109, Gln269, Chain C: Asn109, Gln269, Chain A: Glu161, Chain B: Asp108, Chain C: Glu161, Asp108 |
| **Antiviral Drug** | Chain A: Leu162, Gly160, Val159 | Chain B: Leu162, Gly160, Cys270, Val159 | Chain A: Asn109, Thr158, Asn109, His89, Thr158 | Chain B: Asn109, Gln269 | Chain A: Glu161, Chain B: Asp108, Glu161 |
| **Plasmoquine** | Chain A: Leu162, Gly160 | Chain B: Leu162, Gly160, Cys270, Chain C: Leu162, Gly160, Val159 | Chain A: Asn109, Gln269, His89, Thr158, Ser85 | Chain B: Asn109, Gln269, Chain C: Asn109, Gln269, Chain C: Val159 | Chain A: Glu161, Chain B: Glu161, Chain C: Glu161, Asp108 |
| **Acalabrutinib** | Chain A: Leu162, Gly160, Val159 | Chain B: Leu162, Gly160, Cys270, Val159 | Chain A: Asn109, Thr158, Asn109, His89, Thr158 | Chain B: Asn109, Gln269 | Chain A: Glu161, Chain B: Asp108, Glu161 |
| **Remdesivir** | Chain A: Leu162, Gly160, Val159 | Chain B: Leu162, Gly160, Cys270, Val159 | Chain A: Asn109, Thr158, Asn109, His89, Thr158 | Chain B: Asn109, Gln269 | Chain A: Glu161, Chain B: Asp108, Glu161 |

*Table 8. Continued.*
| Compound          | Mode of Action                      | Hydrophobic                      | Polar               | H-Bond                  | π-π stacking | Charged       |
|-------------------|-------------------------------------|----------------------------------|---------------------|-------------------------|--------------|---------------|
| Primaquine        | Antimalarial                        | ![Primaquine](image)             | ![Primaquine](image) | ![Primaquine](image)    | ![Primaquine](image) | ![Primaquine](image) |
|                   |                                    | Chain A: Ala91, Ala51, Tyr110,   | Chain A: Asn49, Thr50 | Chain A: Tyr110,       | Chain A: Arg108, Arg90, Arg93, Chain B: Arg89, Arg69, Lys66 |
|                   |                                    | Tyr112, Pro118                   |                     | Chain B: Trp133         | Chain B: Lys66 |
|                   |                                    | Chain B: Trp133, Val134, Tyr124,|                     |                          |              |
|                   |                                    | Pro68, His132, Phe67, Gly125     |                     |                          |              |
| Saquinavir        | Anti-HIV Protease inhibitor         | ![Saquinavir](image)             | ![Saquinavir](image) | ![Saquinavir](image)    | ![Saquinavir](image) | ![Saquinavir](image) |
|                   |                                    | Chain A: Tyr112, Pro118, Ala51,  | Chain A: Asn49, Thr50, Ser52 | Chain A: Thr50, Lys66, Chain B: Phe67 | Chain A: Arg108, Arg150, Chain B: Arg69, Lys66 |
|                   |                                    | Tyr110                           |                     |                          | Chain A: Arg108, Arg93, Chain B: Lys66, Arg69 |
|                   |                                    | Chain C: Val159, Tyr173, Trp133, |                     |                          |              |
|                   |                                    | Val134, Tyr124, Ala135, Pro68,   |                     |                          |              |
|                   |                                    | His132, Phe67, Gly70, Gly125     |                     |                          |              |
| Elvitegravir      | Anti-HIV inhibitor                  | ![Elvitegravir](image)           | ![Elvitegravir](image) | ![Elvitegravir](image)  | ![Elvitegravir](image) | ![Elvitegravir](image) |
|                   |                                    | Chain A: Tyr112, Tyr110, Ala51,  | Chain A: Ser52, Thr50, Asn49 | Chain A: Tyr110, Lys66 | Chain A: Arg108, Arg93, Chain B: Lys66, Arg69 |
|                   |                                    | Ala91, Pro152                    |                     |                          |              |
|                   |                                    | Chain B: Phe67, Pro68, Trp133    |                     |                          |              |
|                   |                                    | Chain C: Val159                  |                     |                          |              |
| Imiquimod         | Antibacterial                       | ![Imiquimod](image)              | ![Imiquimod](image)  | ![Imiquimod](image)     | ![Imiquimod](image) | ![Imiquimod](image) |
|                   |                                    | Chain A: Pro118, Ala91, Ala51,   | Chain A: Ser52      | Chain A: Tyr112         | Chain A: Arg150, Arg108, Arg93 Chain B: Arg89, Lys66 |
|                   |                                    | Tyr110, Tyr112                   |                     | Chain B: Lys66          | Chain B: Arg89, Lys66 |
|                   |                                    | Chain B: Pro68, Phe67, Pro169    |                     |                          |              |
| Afatinib          | Tyrosine Kinase inhibitor; Epidermal | ![Afatinib](image)               | ![Afatinib](image)  | ![Afatinib](image)      | ![Afatinib](image) | ![Afatinib](image) |
|                   | Growth Factor Receptor (EGFR) inhibitor |                     |                     |                          |              |
|                   |                                    | Chain A: Tyr110, Ala51, Pro152,  | Chain A: Asn49, Thr167, Gln71 | Chain A: Arg69 | Chain A: Arg150, Arg93, Arg108, Chain B: Arg69, Lys66 |
|                   |                                    | Ala157                           |                     |                          |              |
|                   |                                    | Chain B: Gly70, Pro68, Val159,   |                     |                          |              |
|                   |                                    | Leu162, Leu168, Leu160, Leu57    |                     |                          |              |

(continued)
| Compound | Mode of Action | Hydrophobic | Polar | H-Bond | π-π stacking | Charged |
|----------|---------------|-------------|--------|---------|--------------|---------|
| **Antimalarial** | | | | | | |
| Chain: Leu160, Leu162, Val163, Gly165, Tyr173, Val159, Leu57 | Chain: Gln161, Thr166, Gln164, Thr167 | Chain: Gly165, Thr167 | Chain: B: Glu137, Arg69, Chain A: Arg108 |
| **Antimalarial Drug** | | | | | | |
| Chain: Pro81, Ile75, Pro74, Val73, Pro163, Gly70 | Chain: Gln71, Gln164, Gln84, Ser79, Ser80 | Chain: C: Gln161, Thr166, Gln164, Thr167 | |
| **Anti-arthritis** | | | | | | | Chain: B: Glu137 |
| Chain: Leu168, Pro163, Leu162, Gly165 | Chain: Gln71, Gln164, Gln84, Ser79, Ser80 | Chain: C: Gln161, Thr166, Gln164, Thr167 | |
| **Tyrosine Kinase inhibitor; Epidermal Growth Factor Receptor (EGFR) inhibitor** | | | | | | |
| Chain: Trp133, Tyr124, Pro68, Phe67, Gly125 | Chain: Asn49, Thr50, Ser52, Thr92 | Chain: B: Thr167, Lys66 | Chain: A: Arg93, Arg108, Arg94, Chain B: Arg69, Lys66 |
| **An irreversible Epidermal Receptor Growth Tyrosine kinase** | | | | | | |
| Chain: Val159, Tyr173, Pro118 | Chain: C: Gln161, Chain B: Gln71 | Chain: B: Arg69, Trp133, Phe67 | Chain: B: Lys66, Gly70, Ala135 | Chain: B: Arg69, Lys66 |
| **EKB-569** | | | | | | |
| Chain: Tyr142, Pro118, Ala135, Pro68, Ile132, Phe67, Gly70 | Chain: C: Gln161, Chain B: Gln71 | Chain: A: Asn49, Thr50, Ser52 | Chain: B: Lys66, Gly70, Ala135 | Chain: B: Arg69, Lys66 |

(continued)
Absorption: Primaquine, amodiaquine, and HCQ have high Caco-2 (heterogeneous human epithelial colorectal adenocarcinoma cells) permeability.

Human Intestinal Absorption: All drugs are majorly absorbed by human intestine. (For Ideal drug, HIA percentage should be higher than 30%) and primaquine and amodiaquine are highly absorbed by the intestine.

P-Glycoprotein substrate and Inhibitor: P-Glycoprotein is mainly known as multidrug resistance protein; ATP binding cassette subfamily B member is an integral part of cell membrane which flush out foreign substances out of the cell. The results indicate that only primaquine and HCQ are non-inhibitors substrates for P-Glycoprotein.

Distribution: The Distribution results indicate the following observation.

BBB Permeation: For ideal drug Log BBB value, much be greater than 0.3. All drugs are able to cross the Blood-Brain Barrier.

Metabolism:
CY2D6, CY34A: Cytochrome 450 is an enzyme that is encoded by both CY2D6 and CY34A gene, which are primarily expressed and metabolized in the liver. The results indicate that all drugs are except amodiaquine and primaquine are non-inhibitors to CY2D6 substrate and inhibitor and afatinib, acalabrutinib, and primaquine are non-inhibitors to CY34A substrate.

OATP1B1, OATP1B3: OATP1B1 and OAT1B3 are uptake transporters that are expressed on the sinusoidal site of hepatocytes, and these are responsible for drug uptake and endogenous compounds from the blood. The results indicate that all

![Figure 10. RMSD Plot for all targets of SARS-COV-2 with afatinib drug.](image-url)

Table 10. Docking parameters of top scorer drugs for nucleocapsid protein of SARS-COV-2 (PDB ID 6M3M).

| Drugs       | GScore | DScore | Lipophilic | EVDW | HBond | EModel   |
|-------------|--------|--------|------------|------|-------|----------|
| Primaquine  | 8.51   | 7.58   | 2.56       | 0.86 | 60.692|
| Amodiaquine | 8.5    | 5      | 2.6        | 0.9  | 56.71 |
| Saquinavir  | 7.61   | 6.65   | 4.64       | 1    | 78.879|
| Elvitegravir| 7.57   | 7.44   | 2.76       | 1.4  | 67.765|
| Imiquimod   | 7.29   | 7.03   | 2.14       | 2.98 | 56.262|
| Afinitin    | 7.26   | 6.03   | 3.29       | 0.97 | 58.428|
| Pamaquine   | 7.23   | 7.23   | 5.19       | 1.33 | 81.96 |
| HCQ         | 4.99   | 4.94   | 3.38       | 1.28 | 40.568|
| Remdesivir  | 6.85   | 6.85   | 4.64       | 1.75 | 69.954|
| Acalabrutinib| -5.15 | -5.14  | 4.05       | -0.92| -72.062|
| EKB-569     | -3.58  | -1.76  | 3.91       | -1.1 | -53.435|
| Plasmoquine | -2.63  | -2.4   | -4.43      | -0.96| -56.61 |
3.4. Enrichment studies

Enrichment studies help to assess the active set of compounds statically among large set of databases through virtual screening. The parameters that are calculated through enrichment studies are Receiver Operator Characteristics area under the curve (ROC), Boltzmann-enhanced DiscriminationReceiver Operator Characteristic area under the curve and Enrichment Factor (BERDOC), and Enrichment factor calculated with respect to the number of total ligands. EF = (a/n)/(A/N), where a is the number of actives found in sample size n, A is the total number of actives, and N is the total number of ligands ( decoys and actives). All these parameters are summarized in the Table 13.

The ideal value for BERDOC and ROC parameters should be between 0 and 1. The active ligands among whole databases and decoys with all five targets main protease, spike proteins, RdRp enzymes, papain protease as well as for N protein of SARS-CO-2 have value below 1 which indicates that the active ligands are ideal to work again therapeutics targets of SARS-COV-2. The ROC curves for active ligands with each target are shown in Figure 9.

3.5. Molecular dynamics simulation

The protein-Afatinib complexes: afatinib-5R80, afatinib-6M0J, afatinib-6W9C, and afatinib-7BTF showed very stable RMSD fluctuations (< 3.6 Å) throughout the simulation’s trajectories. Among the four stable complexes, 7BTF and 5R80 had the least variation in the backbone. Afatinib-6M3M complex displayed dramatic RMSD fluctuations (2-8.25 Å with spikes upto 11 Å) during the course of simulations. On visualizing the MD simulation trajectories, it was observed that the high RMSD fluctuations in 6M3M are due to the movement of one of the protein subunits in the protein, though the ligand remained in the active site of the protein. The RMSD fluctuations are shown in Figure 10.

The RMSF fluctuations with respect to the residue number of the protein-ligand (Afatinib) complexes considered for the study is shown in Figure 11. Except for the afatinib-6M0J
Table 12. Interacting amino acids for compounds having G-Score above Hydroxyquinoline and Galidesivir for RNA dependent RNA Polymerase of SARS-COV-2 (PDB ID 7BTF).

| Compound          | Mode of Action              | Hydrophobic       | Polar               | H-Bond               | π-π stacking | Charged            |
|-------------------|----------------------------|-------------------|---------------------|----------------------|--------------|--------------------|
|                   |                            |                   | Tyr455, Ala554, Val557, Tyr619, Pro620, Cys622 | Asp760, Asp760, Arg553, Arg553, Arg555, Asp623, Asp623, Asp623 | Lys621, Arg553, Arg555 | Asp624, Arg553, Arg555, Arg545, Asp452, Asp623, Asp760, Asp761 |
| EKB-569           | Potent Irreversible EFGR receptor |                   | Tyr455, Tyr619, Pro620, Cys622, Ala550 | Ser549               | Lys621, Arg553, Arg555 | Arg624, Arg555, Arg545, Asp452, Asp623, Asp760, Asp761 |
|                   | DNA Topoisomerase inhibitor  |                   | Tyr455, Tyr619, Pro620, Cys622, Ala550 | Asp761, Trp617, Asp760, Lys621, Tyr619 | Arg553, Lys621 | Arg624, Arg555, Arg553, Lys551, Asp623, Asp618, Asp761, Asp760 |
|                   | Antimalarial, Anti-inflammatory |                   | Tyr455, Cys622, Pro620, Tyr619, Trp617, Ala762 | Ser759 | Lys621, Arg553, Arg555, Asp452 | Arg624, Arg562, Lys621, Lys798, Asp623, Asp618, Asp761, Asp760 |
|                   | Antimalarial                |                   | Tyr455, Cys622, Pro620, Tyr619, Trp617, Ala762 | Ser759 | Lys621, Arg553, Arg555, Asp452 | Arg624, Arg553, Arg555, Asp452, Asp623, Asp618, Asp761, Asp760 |
|                   | Antibiotic                  |                   | Tyr455, Ala554, Cys622, Pro620, Tyr619, Trp617, Ala762, Trp800, Phe812, Cys814 | Thr556, Ser682, Ser814 | Lys621, Arg553, Arg555, Asp623, Asp760, Asp761, Trp617 | Arg553, Arg555, Arg624, Lys621, Lys798, Asp452, Asp623, Asp618, Asp761, Asp760, Glu811 |
|                   |                            |                   | Tyr455, Ala554, Cys622, Pro620, Tyr619, Trp617, Ala762, Trp800, Phe812, Cys814 | Thr556, Ser682, Ser814 | Lys621, Arg553, Arg555, Asp623, Asp760, Asp761, Trp617 | Arg553, Arg555, Arg624, Lys621, Lys798, Asp452, Asp623, Asp618, Asp761, Asp760, Glu811 |

(continued)
| Compound          | Mode of Action          | Hydrophobic                  | Polar                  | H-Bond                  | π-π stacking | Charged                  |
|-------------------|-------------------------|------------------------------|------------------------|-------------------------|--------------|--------------------------|
| Elvitegravir      | Anti-HIV inhibitor      | Tyr619, Pro620, Cys622, Tyr455 | Asn691, Thr680, Ser682, Thr556 | Arg553, Asn691, Arg555 | Lys621, Arg553 | Asp618, Asp760, Asp623, Lys621, Arg624, Arg553, Arg555, Lys551 |
| Galidesivir       | Antiviral activity against positive and negative sense RNA viruses for example: Ebola, Marburg, Yellow fever, Zika virus | Tyr619, Pro620, Cys622, Tyr455 | Thr556 | Asp623, Asp618, Tyr619 | | |
| Hydroxychloroquine| Antimalarial Drug        | Cys622, Pro620, Tyr619, Trp617, Trp800, Ala762, Phe812, Cys813 | Ser814 | Asp760, Asp761, Asp761, Asp761, Asp623 | Lys621 | Asp623, Lys621, Asp618, Asp760, Asp761, Glu811, Lys798 |
| Imiquimod         | Toll-like receptor 7 Agonist | Tyr619, Pro620, Cys622, Tyr455 | | Asp623, Arg553, Arg555 | Lys621, Arg553 | Lys621, Asp623, Asp618, Asp760, Glu811, Arg624, Asp760, Asp452 |
| Batefenterol      | β2 adrenoceptors agonist, muscarinic receptor antagonist | Cys622, Pro620, Tyr619, Trp617, Tyr455, Ala554 | Ser759, Asn691, Thr556, Ser814 | Lys621, Asp618, Asp760, Ala554 | Lys621, Tyr455, Arg553 | Lys621, Arg624, Asp623, Asp618, Asp760, Lys551, Arg553, Arg555, Asp618, Asp760, Asp761 |
Table 12. Continued.

| Compound | Mode of Action | Hydrophobic | Polar | H-Bond | 11-11 stacking | Charged |
|----------|----------------|-------------|-------|--------|----------------|---------|
| Anti-HIV Protease Inhibitor | Tyr619, Trp617, Pro620, Cys622, Ala762, Ala688 | Ser682, Thr687, Asn691, Thr556, Ser759 | Asp760, Asp623, Arg553, Arg555, Thr556 | Asp618, Glu811, Lys621, Arg624, Asp623, Lys545, Asp684, Arg555, Arg553, Asp760, Asp761 |
| Saquinavir | Tyrosine Kinase inhibitor; Epidermal Growth Factor Receptor (EGFR) inhibitor | Chain A: Tyr455, Ala554, Ala448 | Chain A: Asn552, Ser451, Asn447, Gln444 | Chain A: Ala554, Asp445 | Chain A: Arg553, Ala554 |
| Afatinib | Tyrosine Kinase inhibitor; Epidermal Growth Factor Receptor (EGFR) inhibitor | Pro620, Cys622, Val166, Tyr455, Ala688 | Ser759, Asn691, Thr680, Ser681, Ser682 | Asp623, Lys621 | Arg553 |
| Acalabrutinib | Antiviral Drug | Tyr619, Val166, Pro620, Cys622, Met626, Tyr455 | Ser759, Thr680, Asn691, Asn552 | Lys798, Lys621, Cys622 | Arg553, Lys621 |
| Remdesivir | | | | | |
complex, it was observed that the active site residues and the ligand displayed RMSF fluctuations. Due to random coil structural elements present in the complexes, which are known to display huge structural fluctuations, we noticed high RMSF fluctuations in these regions. Overall, the stable RMSF profile suggests that the protein-ligand complexes are stable during the course of simulations.

The average number of hydrogen bonds in protein-ligand (Afatinib) complexes 5R80, 6M0J, 6M3M, 6W9C, and 7BTF were 1, 1, 2, 1, and 3, respectively. Thus, the maximum number of hydrogen bond interactions were shown by ligand in complexation with (RdRp) RNA dependent RNA polymerase enzyme of SARS-COV-2 while maintaining several van-der Waals contacts. The number of H-bonds formed in the protein-ligand complexes considered for the study as a function of run-length is shown in Figure 12.

3.6. MM-PBSA calculation

MM-PBSA calculation provide overview about the molecular interaction and free binding energy of Afatinib-protein complex. We computed the Binding free energies of the ligand to the protein via MM-PBSA calculations. We also utilized the last 20 ns of the simulations trajectories and generated 80 frames for processing the data for binding energy calculations. The observed binding free energies were: 5R80 \((-5.44 \pm 0.69\) kcal/mol), 6M0J \((-4.29 \pm 0.38\) kcal/mol), 6M3M \((-7.66 \pm 0.54\) kcal/mol), 6W9C \((-4.16 \pm 0.44\) kcal/mol), and 7BTF \((-11.19 \pm 0.72\) kcal/mol). The high binding free energy of the complex with RNA dependent RNA polymerase (7BTF) from SARS-COV-2 suggested (Table 14) that the afatinib could be helpful most in inhibiting the replication process of single stranded RNA virus.

### 3.6.1. Biological Mechanism by which Afatinib inhibit the activity of SARS-COV-2 (Figure 13)

Afatinib belongs to the tyrosine kinase inhibitor family of medication. It is also used to treat non-small lung cell carcinoma, which maintains mutation in the Epidermal Growth factor receptor in a gene (Roskoski, 2016). SARS-Cov-2 virus, when
entered into the body simultaneously, binds with ACE-2 and TMPRSS-2 receptor through which it penetrates the lungs where it releases its single-stranded RNA virus to start multiplication to form multiple copies of a single-stranded virus. During this multiplication process, RNA of COV-2 binds with Toll-like receptors present in the macrophages, further activating the Bruton Tyrosine Kinase. Bruton Kinase Inhibitor plays an essential role in patients suffering from the coronavirus due to macrophage activation (Roschewski et al., 2020). BTK deals with macrophages signalling and activation, which leads to the hyperinflammatory immune response in corona patients. After activation, BTK sends signals to NF-KB, which triggers various inflammatory cytokines (IL-6, IL-12, IL-8, CCL2, TNF-α). BTK also activates the NLRP3 inflammasomal to secrete the IL1B. A virus-induced hyperinflammatory response or “cytokine storm” may be an important pathogenic mechanism of ARDS in these patients by altering pulmonary macrophages and neutrophils, which can lead to the death of patients (Figure 13).

Hence BTK plays a vital role in the activation of these inflammatory cytokines (Conti et al., 2020). BTK inhibitors can inhibit the activity of BTK signalling from macrophage to other inflammatory Cytokines. Afatinib is a potent Bruton tyrosine kinase inhibitor drug (de Bruin et al., 2020). Afatinib breaks the chain of signalling from macrophages activation to auto-immune cells (IL-6, IL-12, IL-8, CCL2, TNF-α) (de Bruin et al., 2020). Therefore, it inhibits the process of activation and cytokine storm. Afatinib also supports human innate immune system response, thereby helping in controlling in replication and infection of virus therefore expected to enhance the immune response (Roschewski et al., 2020).

4. Conclusion

This study showed that among tested drugs in the present in silico study, Afatinib has the highest binding potential to the main protease of SARS-CoV-2, which is higher than HCQ and remdesivir, respectively. (Figure 14) Likewise, other drugs amodiaquine, saquinavir showed efficient binding with active sites on the main protease, papain protease, and RdRp. Among all the screened drugs, Afatinib serves as the best candidate inhibitor for binding with (a) main protease MPRO of SARS-COV-2 with a GScore of −9.04 kcal/mol. Docking with 7BTF RdRp suggests that EKB-569 has the highest binding with GScore value −8.97 kcal/mol. Docking with papain-like protease PLPRO, (PDB ID 6W9C) amodiaquine and Afatinib are active binders with GScore −8.57 kcal/mol and −8.53 kcal/mol, respectively. Docking with Nucleocapsid proteins of SARS-COV-2 suggests that primaquine and amodiaquine serve as the best inhibitor with GScore −8.51 kcal/mol and remdesivir used as control have GScore −6.8 kcal/mol. From docking analysis, it is concluded that Afatinib, amodiaquine, saquinavir, and primaquine are the best drugs to inhibit the entry replication and transcription of viral genome of SARS-COV-2. Further, as we screened Afatinib could be best candidate to overall inhibit the process of SARS-COV-2. Molecular dynamics simulations of Afatinib drug with each therapeutics target of SARS-COV-2, followed by binding free energy estimations via MM-PBSA methods, suggested that the Afatinib-7BTF complex is the most stable complex with the highest ligand binding energetics.

Acknowledgements

The authors would like to thank Department of Chemistry, University of Delhi, New Delhi, India and Institute of Nuclear Medicine and Allied Sciences, Defense Research Development Organization, New Delhi, India for providing Schrodinger Software and other facilities to accomplish this work. The authors also would like to thank UGC for providing fellowship. The authors one and two have equal contribution.

Disclosure statement

The authors declare no conflict of interest.
References

Alexandi, R., De Mesquita, J. F., Pandian, S. K., & Ravi, A. V. (2020). Quinolines-Based SARS-CoV-2 3CLpro and RdRp Inhibitors and Spike-RBD-ACE2 Inhibitor for Drug-Repurposing Against COVID-19: An in silico Analysis. Frontiers in Microbiology, 11(July), 1796–1715. https://doi.org/10.3389/fmicb.2020.01796

Barnard, R. A., Wittenburg, L. A., Amaravadi, R. K., Gustafson, D. L., Thorburn, A., & Thamm, D. H. (2014). Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. Autophagy, 10(8), 1415–1422. https://doi.org/10.4161/auto.29165

Bhardwaj, V. K., Singh, R., Sharma, J., Rajendran, V., Purohit, R., & Kumar, A. R., Bhattacharya, M., Sharma, G., Lee, S. S., & Alexpandi, R., De Mesquita, J. F., Pandian, S. K., & Ravi, A. V. (2020). Accelerated Molecular Dynamics Simulation for Helical Proteins Folding in Explicit Water. Frontiers in Chemistry, 7(August), 540–518. https://doi.org/10.3389/fchem.2019.00540

Dutta, N. K., Mazumdar, K., & Gordy, J. T. (2020). The Nucleocapsid Protein of SARS-CoV-2: A Target for Vaccine Development. Journal of Virology, 94(13), 1–2. https://doi.org/10.1128/JVI.00647-20

Efiky, A. A. (2020). SARS-CoV-2 RNA dependent RNA polymerase (RdRp) targeting: An in silico perspective. Journal of Biomolecular Structure and Dynamics, 1–9. https://doi.org/10.1080/07391102.2020.1761882

Elzupir, A. O. (2020). Inhibition of SARS-CoV-2 main protease 3CLpro by means of ω-alkanoyl and pyridine-containing pharmaceuticals using in silico molecular docking. Journal of Molecular Structure, 1222, 128878. https://doi.org/10.1016/j.molstruc.2020.128878

Hollingsworth, S. A., & Dror, R. O. (2018). Molecular dynamics simulation for all. Neuron, 99(6), 1129–1143. https://doi.org/10.1016/j.neuron.2018.08.011

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, Y., Yin, W., Li, H., Liu, M., … Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395(10223), 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5 https://doi.org/10.1016/S0140-6736(20)30183-5

Young, I. S., & Cheatham, T. E. (2008). Determination of Alkali and Halide Monovalent Ion Parameters for Use in Explicitly Solvated Biomolecular Simulations. The Journal of Physical Chemistry B, 112(30), 9020–9041. https://doi.org/10.1021/jp8001614

Kang, S., Yang, M., Hong, Z., Zhang, L., Huang, Z., Chen, X., He, S., Zhou, Z., Zhou, Z., Chen, Q., Yan, Y., Zhang, C., Shan, H., & Chen, S. (2020). Crystal structure of SARS-CoV-2 nucleocapsid protein RNA binding domain reveals potential unique drug targeting sites. Acta Pharmacologica Sinica, 10(7), 1228–1238. https://doi.org/10.1002/j.apsb.2020.04.009

Khan, R. J., Jha, R. K., Amera, G. M., Jain, M., Singh, E., Pathak, A., Singh, R. P., Muthukumaran, J., & Singh, A. K. (2020). Targeting SARS-CoV-2: A systematic drug repurposing approach to identify promising inhibitors against 3CL-like proteinase and 2α-O-ribosyltransferase. Journal of Biomolecular Structure and Dynamics, 38(9), 2679–2692. https://doi.org/10.1080/07391102.2019.1675357

Kiplin Guy, R., DiPaola, R. S., Romanelli, F., & Dutch, R. E. (2020). Rapid repurposing of drugs for COVID-19. Science (New York, N.Y.), 368(6493), 829–830. https://doi.org/10.1126/science.abb9332

Ko, W.-C., Rolain, J.-M., Lee, N.-Y., Chen, P.-L., Huang, C.-T., Lee, P.-I., & Hsueh, P.-R. (2020). Arguments in favour of remdesivir for treating SARS-CoV-2 infections. International Journal of Antimicrobial Agents, 55(4), 105933. https://doi.org/10.1016/j.ijantimicag.2020.105933

Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., & Wang, X. (2020). Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature, 581(7807), 215–220. https://doi.org/10.1038/s41586-020-2180-5

Laskowski, R. A., & Swindells, M. B. (2011). LigPlot+: Multiple ligand-protein interaction diagrams for drug discovery. Journal of Chemical Information and Modeling, 51(10), 2778–2786. https://doi.org/10.1021/ci200227u

Law, P. K. (2020). COVID-19 Pandemic: Its Origin, Implications and Treatments. Open Journal of Regenerative Medicine, 09(02), 43–64. https://doi.org/10.4236/ojrm.2020.92006

Liu, J., Cao, R., Xu, M., Wang, X., Zhang, H., Hu, H., Li, Y., Hu, Z., Zhong, W., & Wang, M. (2020). Hydroxychloroquine, a less toxic derivative of
chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. In Cell Discovery. https://doi.org/10.1038/s41421-020-0156-0 Maier, J. A., Martinez, C., Kasavajhala, K., Wickstrom, L., Hauser, K. E., & Simmerling, C. (2015). ffs1458: Improving the accuracy of protein side chain and backbone parameters from ff99SB. Journal of Chemical Theory and Computation, 11(8), 3696–3713. https://doi.org/10.1021/acs.jctc.5b00255 Marella, A., Tanwar, O. P., Saha, R., Ali, M. R., Srivastava, S., Akhter, M., Shaquiquzzaman, M., & Alam, M. M. (2013). Quinoline: A versatile heterocyclic. Arabian Journal of Chemistry, 13(1), 632–648. https://doi.org/10.1016/j.arabjc.2017.07.006

Santhanam, V., Pant, P., Jayaram, B., & Ramesh, N. G. (2019). Design, synthesis and glycosidase inhibition studies of novel triazole fused imino-cyclitol-l-lactams. Organic & Biomolecular Chemistry, 17(5), 1130–1140. https://doi.org/10.1039/c8ob03084g

Sahdeva, C., Wadhwa, A., Kumari, A., Hussain, F., Jha, P., & Kaushik, N. K. (2020). In silico Potential of Approved Antimalarial Drugs for Repurposing Against COVID-19. OMICS: A Journal of Integrative Biology, 24(10), 568–580. https://doi.org/10.1089/omi.2020.0071